Trial reportClinical pharmacology and therapeutics2013
Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics.
Trial report in Clinical pharmacology and therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 68 citations in OpenAlex.
- Plasma Metabolomics Analysis of Aspirin Treatment and Risk of Colorectal Adenomas.Cancer prevention research (Philadelphia, Pa.) · 2022Trial
- Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk.Cancer prevention research (Philadelphia, Pa.) · 2020Trial
- Cytokine and lipid metabolome effects of low-dose acetylsalicylic acid in critically ill patients with systemic inflammation: a pilot, feasibility, multicentre, randomised, placebo-controlled trial.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2020Trial
- Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.Translational psychiatry · 2019Trial
- Pharmacometabolomics of l-carnitine treatment response phenotypes in patients with septic shock.Annals of the American Thoracic Society · 2015Trial
- Article
- Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Transcriptome- and metabolome-based candidate mechanism of BCR-ABL-independent resistance to olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.Functional & integrative genomics · 2023Article
- Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML.Frontiers in oncology · 2021Article
- Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine.Metabolites · 2020Review
- Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.Journal of clinical pharmacology · 2019Article
- Novel Applications of Metabolomics in Personalized Medicine: A Mini-Review.Molecules (Basel, Switzerland) · 2017Review
- The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.Cardiology research and practice · 2017Review
- Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy.Metabolomics : Official journal of the Metabolomic Society · 2017Article
- TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.Molecular psychiatry · 2016Article
- Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.International journal of epidemiology · 2016Review
- Emerging applications of metabolomics in drug discovery and precision medicine.Nature reviews. Drug discovery · 2016Review
- Pharmacometabolomics informs Pharmacogenomics.Metabolomics : Official journal of the Metabolomic Society · 2016Article
- Pharmacometabolomics in Early-Phase Clinical Development.Clinical and translational science · 2016Review
- Metabolomics by Gas Chromatography-Mass Spectrometry: Combined Targeted and Untargeted Profiling.Current protocols in molecular biology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
Abstract
Although aspirin is a well-established antiplatelet agent, the mechanisms of aspirin resistance remain poorly understood. Metabolomics allows for measurement of hundreds of small molecules in biological samples, enabling detailed mapping of pathways involved in drug response. We defined the metabolic signature of aspirin exposure in subjects from the Heredity and Phenotype Intervention Heart Study. Many metabolites, including known aspirin catabolites, changed on exposure to aspirin, and pathway enrichment analysis identified purine metabolism as significantly affected by drug exposure. Furthermore, purines were associated with aspirin response, and poor responders had higher postaspirin adenosine and inosine levels than did good responders (n = 76; both P < 4 × 10(-3)). Using our established "pharmacometabolomics-informed pharmacogenomics" approach, we identified genetic variants in adenosine kinase associated with aspirin response. Combining metabolomics and genomics allowed for more comprehensive interrogation of mechanisms of variation in aspirin response--an important step toward personalized treatment approaches for cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.